ICYMI: 9 big biopharma predictions for 2015, according to industry experts
Happy New Year! 2014 was chock full of game-changing approvals, research advances, and dramatic mergers and acquisitions that fostered increasing biotech and pharmaceutical industry consolidation.
At the end of last year, BioPharma Dive asked its team of experts to weigh in on what they thought were the biggest biotech and pharmaceutical industry "game-changers" of 2014. Now, as we kick off the new year, those same experts are dishing on what they predict will be some of the most significant industry developments in 2015.
Here’s what they had to say (note: you can click on each individual's name to see his or her full-sized picture):
Osnat Benshoshan, Vice President of Marketing at SERMO
"The most important phenomena to arise from physician social networking is medical crowdsourcing and it will hit its stride as physicians connect globally. Doctors will be able to share and solve cases in unprecedented time with teams of cross functional medical experts using their collective wisdom over a technology platform. Peer to Peer influence will reach a whole new level as it won’t just be KOLs influencing doctors, it will be doctors themselves across the country and around the world."
Sean Dalziel, Co-Founder and Managing Partner, Actera Pharmaceuticals
"Beyond Hep C, Gilead charts its course for a bigger presence in oncology including deal-making."
Venkat Gullapalli, MD, CEO, Medikly
"In 2015, the dominance of data-driven intelligence will continue to grow, as will the trend towards multi-channel marketing and non-personal promotion. As the trends pick up speed, the role of sales reps as a primary source of two-way information and interaction will continue to diminish.
As the year unfolds, pharma will become more sophisticated at leveraging the power of web analytics."
Robert Jackson, Experienced Pharmaceutical Sales Representative, Midwest
"I see the trends from 2014—the proliferation of 'no see' policies and greater reliance on non-personal promotion—continuing and accelerating. The pharmaceutical sales representatives who remain will have to change their strategies in order to operate effectively in the new environment. Regardless, there will continue to be a role for sales reps, though it will continually be evolving."
Barry Mennen, MD, a Washington, DC-based physician, with 30 years of experience in the pharmaceutical industry
"I am betting that 2015 will see a breakthrough (or breakthroughs) from the application of big data techniques to diverse biomedical information. The wealth of superdata available from electronic health records, genomics, proteomics, imaging studies, pharmacology, the environment and many other areas will ultimately yield pathways towards therapy and preventive medicine that we cannot begin to imagine now.
Stanford University Medical Center partnering with Silicon Valley will lead the way, and this new year will see discoveries that will get headlines!"
Mark Menning, Co-Founder and Managing Partner, Actera Pharmaceuticals
"Always keep an eye out for Gilead. Others may have Solvadi and Harvoni on their list but I expect Gilead to come out of left field again in an area nobody was suspecting. A classic Gilead move."
Leigh Purvis, Director, Health Services Research, AARP Public Policy Institute
"The health care system cannot continue simply absorbing the costs associated with expensive medications. As more and more of them hit the market, we’re going to hear increasing calls to start finding ways to ensure that we’re using these products—and all health care—more effectively."
Cornelia Reininger, MD, PhD, Chief Medical Officer, Navidea Biopharmaceuticals
"2015 is primed to be another exciting period of widespread precision diagnostic adoption. In drug development efforts for instance, the use of imaging CNS biomarkers has become broadly accepted for detection of beta-amyloid and tau. These efforts will ultimately enable drug developers to use globally recognized standards to identify the correct patients most suitable for their indication and more rapidly advance their products into routine clinical use."
Richard Wasserman, MD, Clinical Professor of Pediatrics at the University of Texas Southwestern Medical School
"After a lag—until providers become familiar with the product—HyQvia will cannibalize much of the current IGSC (subcutaneous administration of immunoglobulin) market and expand into off-label use before clinical trials have been completed."